版本:
中国

BRIEF-Fibrocell completes dosing of first cohort in phase 1/2 clinical trial of FCX-007 gene therapy

June 8 Fibrocell Science Inc

* Fibrocell completes dosing of first cohort in phase 1/2 clinical trial of FCX-007 gene therapy for treatment of recessive dystrophic epidermolysis bullosa

* No product-related adverse events were reported

* 12-week post-treatment data for safety, mechanism of action and efficacy for multiple patients in phase 1 portion of trial expected in Q3 of 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐